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Abstract: Venous thromboembolism, presenting as deep vein thrombosis or pulmonary 
embolism, is a major challenge for health care systems. It is the third most common vascular 
disease after coronary heart disease and stroke, and many hospitalized patients have at least 
one risk factor. In particular, patients undergoing hip or knee replacement are at risk, with an 
incidence of asymptomatic deep vein thrombosis of 40%–60% without thromboprophylaxis. 
Venous thromboembolism is associated with significant mortality and morbidity, with patients 
being at risk of recurrence, post-thrombotic syndrome, and chronic thromboembolic pulmonary 
hypertension. Arterial thromboembolism is even more frequent, and atrial fibrillation, the most 
common embolic source (cardiac arrhythmia), is associated with a five-fold increase in the risk 
of stroke. Strokes due to atrial fibrillation tend to be more severe and disabling and are more 
often fatal than strokes due to other causes. Currently, recommended management of both venous 
and arterial thromboembolism involves the use of anticoagulants such as coumarin and heparin 
derivatives. These agents are effective, although have characteristics that prevent them from 
providing optimal anticoagulation and convenience. Hence, new improved oral anticoagulants 
are being investigated. Dabigatran is a reversible, direct thrombin inhibitor, which is adminis-
tered as dabigatran etexilate, the oral prodrug. Because it is the first new oral anticoagulant that 
has been licensed in many countries worldwide for thromboprophylaxis following orthopedic 
surgery and for stroke prevention in patients with atrial fibrillation, this compound will be the 
main focus of this review. Dabigatran has been investigated for the treatment of established 
venous thromboembolism and prevention of recurrence in patients undergoing hip or knee 
replacement, as well as for stroke prevention in atrial fibrillation patients with a moderate and 
high risk of stroke.
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Introduction
This review will summarize the efficacy and safety data available for dabigatran 
etexilate (herein after referred to as dabigatran) as anticoagulation therapy for the 
prevention and treatment of venous thromboembolism and for stroke prevention in 
patients with atrial fibrillation. To provide a broader picture of this rapidly advancing 
area of therapy, we have included a brief overview of recent data on other new oral 
anticoagulants.
Two million people per year in the United States are affected by venous 
thromboembolism (deep vein thrombosis or pulmonary embolism), making venous 
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thromboembolism the third most common vascular disease 
after coronary heart disease and stroke.1 In Europe, the 
number of deaths resulting from venous thromboembolism 
is five times greater than the combined total deaths from 
breast cancer, acquired immune deficiency syndrome, and 
road traffic accidents.2
The consequences of developing venous thromboembo-
lism are clinically important. Patients diagnosed with venous 
thromboembolism, especially pulmonary embolism, are at 
greater risk of death within the first 3 months than patients 
without venous thromboembolism,3 and patients with venous 
thromboembolism can develop long-term complications, such 
as post-thrombotic syndrome and chronic thromboembolic 
pulmonary hypertension.4–6 Furthermore, approximately 18% 
of patients will have recurrences of venous thromboembolism 
within 2 years, and one third of patients within 8 years.7
Venous thromboembolism  
in orthopedic surgery
Without thromboprophylaxis, major orthopedic surgery, such 
as total hip or knee replacement (THR or TKR), carries a risk 
of asymptomatic venous thromboembolism. This is because 
orthopedic surgery triggers a substantial local and systemic 
thrombin generation and activity, potentially leading to 
manifestation of thrombotic events on both the venous and 
arterial side.8,9 The relationship between asymptomatic and 
symptomatic venous thromboembolism has recently been 
demonstrated using data from prospective randomized trials, 
ie, one symptomatic venous thromboembolism developed for 
every five occurrences of asymptomatic deep vein thrombosis 
after THR, and for every 21 occurrences after TKR.10
Even if clinical events have decreased in recent 
years,11 rebound thrombin activity has been shown when 
prophylaxis with dalteparin was suspended at hospital 
discharge about one week post-surgery.9 Likely as a result 
of the early discontinuation of thromboprophylaxis,12 venous 
thromboembolism is the most common cause of readmission 
to hospital in patients who have undergone such surgery.13–15 
In a study of patients who had undergone major hip and knee 
surgery with hospital-based thromboprophylaxis, most cases of 
venous thromboembolism developed after hospital discharge, 
confirming the need for continued thromboprophylaxis. The 
increased risk of venous thromboembolism was apparent 
for about 3 months after hip surgery and 1 month after knee 
surgery.11 Similarly, the increased absolute rate of deaths 
after THR (ie, in the same patient population between 100 
and 200 days) was dominated by vascular events and lasted 
for about 3 months.11,16
In tandem with the increasing age of the population, the 
number of THR and TKR procedures is increasing in many 
countries, and this is likely to have a major impact on the 
number of patients experiencing postoperative systemic 
thromboembolic events.17–20
Stroke in patients with atrial 
fibrillation
Stroke is an arterial thromboembolic disease and a major 
complication of nonvalvular atrial fibrillation.21 Atrial 
fibrillation is the most common cardiac arrhythmia, affecting 
an estimated 4.5 million people in Europe and 2.3 million in 
the United States.22,23 Because the prevalence increases with 
age, it is predicted to increase significantly over the next 
40 years as a result of the growing elderly population.22
According to age-adjusted rates from the Framingham 
Heart Study, patients with atrial fibrillation have a five-fold 
increase in risk for embolic stroke.21 It is estimated that atrial 
fibrillation may account for 45% of all embolic strokes and 
for 15%–20% of all strokes.24 Stroke due to atrial fibrillation 
tends to be particularly severe and disabling, and more 
likely to be fatal than strokes not due to atrial fibrillation.25,26 
Patients with atrial fibrillation are at an increased risk of 
stroke because of the prothrombotic state that is associated 
with this condition, and this leads to a greater risk of thrombus 
formation.27–29 Without effective anticoagulation therapy, the 
average incidence of stroke in atrial fibrillation patients is 5% 
per year.30 In addition to being associated with an increased 
risk of stroke, atrial fibrillation is associated with an increased 
risk of heart failure, death, and cognitive dysfunction, as well 
as a reduced quality of life.21,31–34
Need for appropriate 
anticoagulation
The need for effective anticoagulation therapy across 
multiple thromboembolic disease indications is clearly 
evident. A central and critical step in the coagulation cascade 
is the conversion of fibrinogen to fibrin, which is mediated 
by thrombin. Fundamental to hemostasis is the balance 
between fibrin deposition and removal, which protects the 
vascular system from blood loss at the site of an injury, whilst 
maintaining blood fluidity.
An objective of treatment with an anticoagulant agent 
is to optimize the balance between efficacy (prevention 
of thrombus formation) and safety (ie, bleeding and 
adverse events). For many years, coumarin derivatives 
(the vitamin K antagonists) have been the only oral agents 
available for long-term anticoagulation therapy. Although the 
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vitamin K antagonists are effective, their use is limited by 
their slow onset and offset of action, narrow therapeutic 
window, multiple drug and food interactions, unpredictable 
anticoagulant effect (which may cause severe bleeding), 
and requirement for regular anticoagulant monitoring 
and dose adjustment.35 Patients not maintained within the 
therapeutic window remain at risk of thromboembolism 
(under-anticoagulated) or have an increased risk of bleeding 
(over-anticoagulated).36
The heparin derivatives, although differing in their 
side effect profiles, as a class have their main drawback in 
long-term use, since they are only available as injectable 
compounds. Such limitations to providing optimal 
anticoagulation have motivated the search for improved oral 
anticoagulants.
Direct thrombin inhibition has been established as an 
effective approach to anticoagulation therapy because of the 
central role that thrombin plays in thrombus formation during 
hemostasis, thrombosis, and inflammation. Dabigatran is the 
first available oral direct thrombin inhibitor approved for 
marketing for the prevention of venous thromboembolism 
following orthopedic surgery and for prevention of arterial 
embolism and stroke in patients with atrial fibrillation. 
It is currently under investigation for the prevention and 
treatment of other types of venous and arterial thrombosis.37,38 
Dabigatran offers potential advantages over currently 
available anticoagulants because it is administered orally 
and its predictable anticoagulant effect abrogates the need for 
coagulation monitoring. After major orthopedic surgery it has 
favorable, slow postoperative onset with delayed absorption 
and a reduced plasma peak concentration that does not tend 
to disturb the ongoing hemostatic process. This contrasts 
with a rapid onset of action in nonsurgical patients where 
such an effect is wanted.39–41
Dabigatran for prevention of venous 
thromboembolism post orthopedic 
surgery
Effective anticoagulation reduces the risk of developing 
venous thromboembolism following orthopedic surgery 
and is recommended in evidence-based guidelines.42 Based 
on the efficacy and safety data from a number of pivotal 
trials with enoxaparin 40 mg once daily as comparator, 
dabigatran was initially approved by Health Canada and the 
European Medicines Agency in 2008 for use in the preven-
tion of venous thromboembolism following THR and TKR 
surgery and is now available in more than 75 countries. The 
results from trials in elective major joint surgery showed   
that dabigatran (150 mg and 220 mg once daily) has similar 
efficacy compared with the low molecular weight heparin, 
enoxaparin (40 mg once daily, initiated preoperatively) in 
adults with normal renal function.43,44 In patients with reduced 
kidney function and the elderly, regulatory authorities have 
recommended the lower dabigatran dose (150 mg) to avoid 
drug accumulation and risk of bleeding complications.45
In the RE-MODEL™ trial in patients undergoing TKR, 
the primary efficacy outcome, the composite of total venous 
thromboembolism and mortality, occurred in 37.7% (193/512) 
of the enoxaparin group compared with 36.4% (183/503) 
of the dabigatran 220 mg group and 40.5% (213/526) of 
the dabigatran 150 mg group.44 In this trial, both doses 
of dabigatran were noninferior to enoxaparin on the basis of 
prespecified noninferiority criteria. In addition, rates of the 
secondary efficacy outcome, major venous thromboembolism 
and venous thromboembolism-related mortality, were 
also similar (3.5% for enoxaparin and 2.6% and 3.8% for 
dabigatran 220 mg and 150 mg, respectively).44
In the RE-NOVATE® I trial in THR, the primary efficacy 
outcome occurred in 6.7% (60/897) of the enoxaparin group 
compared with 6.0% (53/880) of the dabigatran 220 mg group 
and 8.6% (75/874) of the dabigatran 150 mg group.43 As in the 
RE-MODEL trial, both doses of dabigatran were noninferior 
to enoxaparin, and rates of major venous thromboembolism 
and venous thromboembolism-related mortality were 
also similar (3.9% for enoxaparin and 3.1% and 4.3% for 
  dabigatran 220 mg and 150 mg, respectively).43
A more recent trial in total hip replacement, RE-NOVATE II,   
confirmed the noninferiority of dabigatran 220 mg. The 
primary efficacy outcome occurred in 8.8% (69/785) of 
the enoxaparin group compared with 7.7% (61/792) of 
the dabigatran group. Moreover, dabigatran was superior 
to enoxaparin for the clinically relevant endpoint of major 
venous thromboembolism and venous thromboembolism-
related death (4.2% for enoxaparin and 2.2% for dabigatran 
220 mg).46 Similar results for the more clinically relevant 
endpoint were also supported by a pooled analysis of 
RE-MODEL, RE-NOVATE I, and RE-MOBILIZE®47 (the 
latter trial compared dabigatran with a postoperative regimen 
of enoxaparin 30 mg twice daily [as used in the United 
States]).48
In terms of safety, all of these trials showed similar 
perioperative bleeding rates to enoxaparin 40 mg once daily 
(Table 1). In the RE-MODEL trial, major bleeding events 
(including surgical site bleeds from preoperative baseline) 
occurred in 1.3% of the enoxaparin group compared with 
1.5% of the dabigatran 220 mg group and 1.3% of the 
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dabigatran 150 mg group.44 In the RE-NOVATE I trial, 
major bleeding occurred in 1.6% of the enoxaparin group 
compared with 2.0% of the dabigatran 220 mg group and 
1.3% of the dabigatran 150 mg group.43 In RE-NOVATE II, 
major bleeding occurred in 0.9% of the enoxaparin group 
compared with 1.4% of the dabigatran 220 mg group.46 Data 
for the composite of major and clinically relevant bleeding 
events are also given in Table 1, and bleeding definitions are 
given in the footnote to the Table.
Many patients undergoing THR or TKR are at increased 
risk of bleeding because of older age and potential reduction 
in renal function, which also decreases with age. A pooled 
analysis from the RE-MODEL and RE-NOVATE I trials 
showed that in patients older than 75 years and in those 
with moderate renal impairment, dabigatran 150 mg once 
daily was as effective as enoxaparin but with significantly 
less bleeding.49
Dabigatran (220 mg and 150 mg once daily) is approved 
in many countries for use in the prevention of venous throm-
boembolism in patients undergoing hip or knee replacement 
surgery. The 220 mg once daily dose is recommended for 
the majority of patients, while the 150 mg once daily dose 
is recommended for patients older than 75 years, with mod-
erate renal impairment, or taking concomitant verapamil, 
quinidine, or amiodarone. Treatment can be initiated within 
1–4 hours of surgery with a half dose and continued from 
the following day with the full dose.45 Or, if preferred, low 
molecular weight heparin can be injected and switched to 
dabigatran at any postoperative day. Because no data are 
available, it is not recommended to start the administration 
of dabigatran until the next dose of parenteral anticoagulant 
would have been due.45
In summary, dabigatran is an effective oral anticoagulation 
therapy for venous thromboembolism prevention following 
major joint replacement surgery. Clinical trials have shown 
that dabigatran offers thromboprophylaxis comparable with 
enoxaparin 40 mg once daily with a similar or improved safety 
profile following hip or knee replacement surgery. Dabigatran 
can be conveniently administered, and a lower dose (150 mg 
once daily) is available for older patients and those with 
moderate renal impairment or taking strong P-glycoprotein 
inhibitors, as supported by the assessment of the European 
Medicines Agency for dabigatran.50 Similarly, the European 
Medicines Agency has recently recommended the use of a 
lower dose of fondaparinux (1.5 mg rather than 2.5 mg) in 
elderly patients as a result of evidence on bleeding events 
from postmarketing reports.51
Other new anticoagulants 
Another novel oral anticoagulant agent licensed for venous 
thromboembolism prevention following orthopedic surgery is 
rivaroxaban, which is a direct factor Xa inhibitor.52 Rivaroxa-
ban was started 6–8 hours after surgery and compared with 
enoxaparin 40 mg once daily started 12 hours before surgery 
in three trials, ie, RECORD 1, 2, and 3,53–55 and with enox-
aparin 30 mg twice daily started 12–24 hours after surgery 
in one trial (RECORD 4).52 Only one dose of rivaroxaban is 
licensed. It appears to be safe and convenient, but concerns 
have been raised over the potential for increased bleeding 
and wound complications.56–62 The study investigators cite 
differences in the definition of major bleeding and statistical 
methodology as possible reasons for the different interpreta-
tions of bleeding data from the rivaroxaban program.61 To 
investigate this further, a meta-analysis of pivotal studies 
Table 1 Rates of bleeding in clinical trials comparing dabigatran with enoxaparin 40 mg once daily for primary prevention of venous 
thromboembolism43,44,46
Dabigatran 220 mg  
once daily
Dabigatran 150 mg  
once daily
Enoxaparin 40 mg   
once daily
RE-NOVATE® I trial
Major bleeding, %a 2.0 1.3 1.6
Major bleeding plus clinically relevant nonmajor bleeding, % 6.2 6.0 5.0
RE-NOVATE® II trial
Major bleeding, %b 1.4 – 0.9
Major bleeding plus clinically relevant nonmajor bleeding, % 3.7 – 2.9
RE-MODEL™ trial
Major bleeding, %b 1.5 1.3 1.3
Major bleeding plus clinically relevant nonmajor bleeding, % 7.4 8.1 6.6
Notes: aOne fatal bleeding event in each dabigatran group, no bleeding into critical organs; bno fatal bleeding, one critical organ bleed in the dabigatran 150 mg group. 
Major bleeding during the treatment period was defined as clinically overt bleeding associated with $20 g/L fall in hemoglobin; clinically overt leading to transfusion of $2 
units packed cells or whole blood; fatal, retroperitoneal, intracranial, intraocular, or intraspinal bleeding; bleeding warranting treatment cessation or leading to reoperation. 
Clinically relevant nonmajor bleeding events were defined as spontaneous skin hematoma $25 cm2; wound hematoma $100 cm2; epistaxis .5 minutes; spontaneous 
macroscopic hematuria or that lasting .24 hours if associated with an intervention; spontaneous rectal bleeding; gingival bleeding .5 minutes; or any other bleeding event 
judged as clinically significant by the investigator.
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comparing dabigatran with enoxaparin or rivaroxaban with 
enoxaparin for venous thromboembolism prevention after 
THR or TKR was undertaken using bleeding rates relative 
to those caused by the same dose of enoxaparin for each 
compound. Because no standardized bleeding definitions 
exist and no head-to-head studies have been conducted, it 
is not possible to perform direct comparisons of dabigatran 
and rivaroxaban. This analysis demonstrated that dabigatran 
shows similar rates of efficacy and bleeding to enoxaparin, 
while rivaroxaban is more effective than enoxaparin but has 
a significantly higher risk of bleeding.58,63 Recently, a signifi-
cantly increased rate of wound-related complications was 
reported by an orthopedic group based in the United King-
dom.59 Whether this increased risk of bleeding and related 
complications is due to the dose being too high, the timing 
of the first dose, or other aspects related to its pharmacology, 
needs to be addressed in further studies.56,57,64 The US Food 
and Drug Administration has requested a lower-dose rivar-
oxaban tablet (5 mg) to be developed to allow dose titration 
in populations at risk of increased drug exposure.65
Two trials have compared apixaban 2.5 mg twice daily 
started 12–24 hours after surgery with enoxaparin 40 mg 
once daily subcutaneously started 12 hours preoperatively. 
The ADVANCE-2 and ADVANCE-3 trials in TKR and THR 
surgery demonstrated that apixaban is more effective than 
the enoxaparin regimen for the primary efficacy outcome 
(asymptomatic and symptomatic deep vein thrombosis, 
nonfatal pulmonary embolism, and all-cause death), with no 
significant difference in the rate of major or clinically relevant 
bleeding (as specified in the trial) between the two treat-
ments.66,67 The late initiation of the compound in this regimen 
is more similar to the United States treatment protocol, where 
late postoperative initiation of enoxaparin has been practiced. 
A comparison with the United States enoxaparin regimen 
(30 mg twice daily subcutaneously initiated 12–24 hours 
after surgery) in TKR was made in the ADVANCE-1 trial. It 
did not meet the noninferiority efficacy criteria but showed 
some slightly lower bleeding parameters.68
Any direct comparisons of results between recent 
trials are impossible because of a variety of study-specific 
bleeding definitions and the lack of international endpoint 
standardization and standard operating procedures.69,70 
Only postmarketing reports will establish the benefits 
and drawbacks of the new compounds in nonselected 
patients. The compounds will also show their robustness 
in daily practice and when hospital drug application 
routines may deviate from the recommended application   
schedules.
Dabigatran in acute venous 
thromboembolism
The goals of anticoagulant treatment in venous thrombo-
embolism are to prevent the thrombus from increasing in size 
and embolizing, to prevent recurrence of deep vein throm-
bosis and pulmonary embolism, and to reduce the occurrence 
of long-term complications.71 Current treatment guidelines 
recommend a rapidly acting parenteral heparin derivative 
for 5–7 days with overlapping treatment using a vitamin K 
antagonist that is continued for at least 3 months, depending 
on the underlying cause and presence of risk factors.72
Recent results from the RE-COVERTM trial, a randomized, 
double-blind, noninferiority trial, show that dabigatran is 
as effective as warfarin for the treatment of acute venous 
thromboembolism. The study included 2564 patients who 
had acute, symptomatic, objectively verified proximal deep 
vein thrombosis of the legs or pulmonary embolism, in 
whom 6 months of anticoagulation therapy was considered 
appropriate. Patients were initially treated with parenteral 
anticoagulation therapy (low molecular weight heparin, 
unfractionated heparin, or fondaparinux) for at least 5 days 
and until international normalized ratio (INR) or sham 
INR exceeded 2.0, followed by 6 months of therapy with 
either 150 mg dabigatran twice daily or warfarin (target 
INR 2.0–3.0).73 This strategy was chosen to protect patient 
safety by using the accepted gold standard therapy during 
the first few days when patients are most at risk. A previous 
study showed that ximelagatran, when administered without 
initial parenteral therapy in acute venous thromboembolism, 
is associated with a higher early rate of recurrent venous 
thromboembolism than enoxaparin followed by warfarin.74
In the RE-COVER trial, the primary efficacy outcome 
(6-month incidence of recurrent symptomatic, objectively 
confirmed venous thromboembolism and venous thrombo-
embolism-related deaths) occurred in 2.4% (30/1274) of 
the dabigatran 150 mg twice daily group compared with 
2.1% (27/1265) of the warfarin group (P , 0.001 for 
noninferiority, Figure 1A).73 While rates of major bleeding 
were similar, 1.6% in the dabigatran group compared with 
1.9% in the warfarin group (hazard ratio with dabigatran 
at 6 months 0.82; 95% confidence interval [CI] 0.45–1.48; 
P = 0.38), major or clinically relevant nonmajor bleeding 
was significantly lower with dabigatran (5.6%) than warfarin 
(8.8%; hazard ratio at 6 months: 0.63; 95% CI 0.47–0.84; 
P = 0.002). Episodes of any bleeding occurred in 16.1% of 
the dabigatran group compared with 21.9% of the warfarin 
group (hazard ratio at 6 months: 0.71; 95% CI 0.59–0.85; 
P , 0.001, Figure 1B). There were no cases of intracranial 
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Figure  1  Incidence  of  (A)  combined  confirmed  venous  thromboembolism  and  venous  thromboembolism  death,  and  (B)  any  bleeding  in  the  RE-COVER™  trial. 
(Schulman S, et al. N Engl J Med. 2009;361(24):2342–2352,73 with permission from the Massachusetts Medical Society).
hemorrhage in the dabigatran group, compared with three 
in the warfarin group.73
In summary, the results of the RE-COVER trial support 
the use of dabigatran as an oral fixed-dose anticoagulant for 
the long-term treatment of acute venous thromboembolism. 
Dabigatran was as effective as dose-adjusted warfarin with 
a significantly lower rate of major or clinically relevant 
bleeds, and of any bleeding.73 In addition, the pharmacologic 
characteristics of dabigatran mean that it is likely to be 
more   convenient to use than dose-adjusted warfarin in the 
real-world setting.73 Switching from low molecular weight 
heparin to dabigatran, as in the treatment of venous 
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thromboembolism after initial treatment with an injectable 
agent, is straightforward; dabigatran is administered at the 
time of the next scheduled dose of parenteral anticoagulant.45 
A second study of dabigatran for the treatment of acute 
venous thromboembolism, RE-COVER II, is underway and 
expected to be complete in 2011.
Studies are also investigating the efficacy and safety 
of dabigatran for the secondary prevention of venous 
thromboembolism compared with placebo and warfarin 
(RE-MEDYTM and RE-SONATETM). The RE-MEDY trial 
compares dabigatran (150 mg twice daily) with dose-adjusted 
warfarin (INR of 2.0–3.0) for the secondary prevention of 
venous thromboembolism in 2700 patients who have been 
successfully treated with an anticoagulant for 3–12 months 
for confirmed acute symptomatic venous thromboembolism. 
Treatment duration is up to 36 months and the primary 
efficacy outcome is the composite incidence of recurrent 
symptomatic deep vein thrombosis/pulmonary embolism and 
venous thromboembolism-related death, which have been 
objectively confirmed by a definitive diagnostic evaluation.75 
The RE-SONATE trial includes approximately 1800 patients 
with symptomatic deep vein thrombosis or pulmonary embo-
lism who have completed 6–18 months of treatment with a 
vitamin K antagonist. These patients are to be randomized 
to double-blind dabigatran (150 mg twice daily) or placebo 
for 6 months. The primary efficacy outcome is the 6-month 
incidence of recurrent symptomatic, objectively confirmed 
venous thromboembolism.76
Other new anticoagulants
Two Phase III studies of rivaroxaban in venous thromboembo-
lism treatment or secondary prevention have been completed. 
EINSTEIN-DVT was an open-label trial of 3449 patients 
with acute symptomatic deep vein thrombosis randomized to 
rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once 
daily) or to enoxaparin followed by a vitamin K antagonist 
for up to 12 months. Rivaroxaban was noninferior for pre-
vention of recurrent venous thromboembolism (2.1% versus 
3.0% with enoxaparin/vitamin K antagonist), while the rates 
of the composite of major and clinically relevant nonmajor 
bleeding were similar between groups (8.1% each).77 In 
the double-blind EINSTEIN-Extension trial, 1196 patients 
who had undergone 6–12 months of treatment for venous 
thrombo  embolism were assigned to rivaroxaban 20 mg once 
daily or placebo for an additional 6–12 months. Rivaroxaban 
was superior for efficacy (1.3% versus 7.1%) and statisti-
cally similar to placebo for major bleeding (0.7% versus 
0%, respectively; P = 0.11). The composite of first major 
and clinically relevant nonmajor bleeding events was more 
frequent with rivaroxaban than with placebo (6.0% versus 
1.2%; hazard ratio 5.19; 95% CI 2.3–11.7; P , 0.001).77
Dabigatran for stroke prevention  
in atrial fibrillation
Current guidelines for the prevention of stroke and other 
thromboembolic complications in patients with atrial 
fibrillation recommend treatment with a vitamin K antagonist 
(eg, warfarin) or aspirin depending on the level of stroke 
risk.23,30,69,70,78–80 The most recent guidelines from The 
Canadian Cardiovascular Society and the American College 
of Cardiology Foundation/American Heart Association/Heart 
Rhythm Society include recommendations for dabigatran 
as an alternative, and potentially a preferred alternative, to 
warfarin.78,80 As already discussed, conventional therapies 
have many limitations, and in particular central nervous 
system bleeding in patients taking vitamin K antagonists is 
a feared complication, so there is a clear clinical need for 
new safe oral anticoagulant agents.
The RE-LY® trial was a Phase III, multicenter, prospective, 
randomized, open-label, blinded, endpoint-adjudication trial 
in 18,113 patients with nonvalvular atrial fibrillation and at 
least one risk factor for stroke.81 Treatment with dabigatran 
(150 mg twice daily) was associated with a significantly lower 
rate of stroke and systemic embolism than warfarin (1.11% 
per year versus 1.71% per year; relative risk 0.65; 95% CI 
0.52–0.81; P , 0.001 for superiority, Figure 2).81,82 The rate 
of stroke and systemic embolism was 1.54% in the dabigatran 
110 mg twice daily group (relative risk 0.90; P , 0.001 for 
noninferiority; P = 0.30 for superiority). Dabigatran 150 mg 
twice daily was associated with a longer time to first stroke or 
systemic embolism than warfarin (relative risk reduction of 
35%).81 Both doses of dabigatran had significantly lower rates 
of hemorrhagic stroke than dose-adjusted warfarin (dabigatran 
110 mg: 0.12% per year, P , 0.001 for superiority; dabigatran 
150 mg: 0.10%, P , 0.001 for superiority; warfarin: 0.38% 
per year). In terms of vascular mortality, treatment with dose-
adjusted warfarin was associated with a rate of 2.69% per year 
compared with 2.43% per year for dabigatran 110 mg (P = 0.21 
for superiority) and 2.28% per year for dabigatran 150 mg 
(P = 0.04 for superiority versus warfarin).81,82 A prespecified 
subgroup analysis of the RE-LY trial demonstrated that the 
benefit of dabigatran compared with dose-adjusted warfarin 
was maintained whether patients were vitamin K antagonist-
naïve or -experienced prior to entering the study.83
Furthermore, both dabigatran doses showed a significant 
reduction in intracranial hemorrhage compared with 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
51
Dabigatran in venous and arterial thromboembolismVascular Health and Risk Management 2012:8
dose-adjusted warfarin (Figure 3). Dabigatran was also 
associated with significantly lower rates of life-threatening 
bleeding (relative risk 0.67 for dabigatran 110 mg and 
0.80 for 150 mg), and total bleeding (relative risk 0.78 for 
dabigatran 110 mg and 0.91 for 150 mg). Treatment with 
dabigatran 150 mg twice daily was associated with a similar 
rate of major bleeding compared with warfarin (3.32% per year 
versus 3.57% per year; P = 0.31), while dabigatran 110 mg 
twice daily was associated with a significantly lower major 
bleeding rate (2.87% versus 3.57% per year; P = 0.003).81,82
Dabigatran has not been evaluated for the initial treatment 
of stroke in patients with atrial fibrillation. However, about 
20% of patients in RE-LY had a previous stroke or transient 
ischemic attack before entering the study, and dabigatran 
was effective for secondary prevention in these patients. 
A subgroup analysis showed that the effects of dabigatran 
in patients who had a previous stroke or transient ischemic 
attack before entering RE-LY were consistent with those of 
other patients in the study.84
In summary, dabigatran 110 mg twice daily shows similar 
efficacy to warfarin for stroke prevention in patients with atrial 
fibrillation but with significantly lower rates of major bleeding. 
Dabigatran 150 mg twice daily is significantly more effective 
than warfarin and associated with similar rates of major 
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bleeding. Significant reductions in the risks of hemorrhagic 
stroke, intracranial hemorrhage, and total bleeding events 
were seen with both doses of dabigatran.81,85
Dabigatran has been approved for stroke prevention in 
patients with atrial fibrillation in the United States, Canada, 
and the European Union at a usual dose of 150 mg twice 
daily. In the United States, the recommended dose for 
patients with severe renal impairment is 75 mg twice daily.86 
In Canada and Europe, the dose recommended for patients 
$80 years of age or at higher risk of bleeding is 110 mg 
twice daily.87
Other new anticoagulants
The results of the ROCKET-AF trial of rivaroxaban 
20 mg once daily versus warfarin for stroke prevention 
have been presented. Patients included in this trial had a 
higher stroke risk than those in RE-LY, ie, either a prior 
stroke, transient ischemic attack, or systemic embolism, 
or at least two other stroke risk factors. Rivaroxaban was 
shown to be noninferior to warfarin for prevention of stroke 
or systemic embolism (1.71% per year versus 2.16% per 
year, respectively). However, it was not superior to warfarin 
in the conventional intention-to-treat analysis (although it 
achieved statistical superiority in an on-treatment analysis). 
Rates of major bleeding (3.60% per year versus 3.45% per 
year, respectively) and nonmajor clinically relevant bleeding 
(11.80% per year versus 11.37% per year, respectively) were 
similar between treatments, while intracranial hemorrhage 
was reduced with rivaroxaban (0.49% per year versus 0.74% 
per year, respectively; P = 0.019).88
The AVERROES trial compared apixaban 5 mg twice 
daily with aspirin in patients with atrial fibrillation who 
were at increased risk for stroke and for whom vitamin K 
antagonist therapy was deemed to be unsuitable. Apixaban 
was superior to aspirin for prevention of stroke or systemic 
embolism (1.6% per year versus 3.7% per year, respectively) 
with similar rates of major bleeding (1.4% per year versus 
1.2% per year) and similar rates of intracranial hemorrhage   
(11 versus 13 events).89
The ARISTOTLE trial included patients with atrial fibril-
lation and at least one additional risk factor for stroke. Patients 
in the apixaban 5 mg twice daily group had fewer stroke 
or systemic embolic events compared with patients taking 
warfarin (1.27% per year versus 1.6% per year, respectively). 
Lower rates of major bleeding ([apixaban] 2.13% per year 
versus [warfarin] 3.09% per year) and intracranial hemor-
rhage (0.33% per year versus 0.80% per year, respectively) 
were also reported.90
Interestingly, the ARISTOTLE results also showed a 
decreased overall mortality in patients treated with apixaban 
as compared with warfarin (3.52% per year versus 3.94% 
per year; P = 0.047). The RE-LY trial also showed almost 
the same decreased overall mortality with dabigatran 150 mg 
twice daily compared with warfarin (3.6% per year versus 
4.13% per year; P = 0.051) although this did not reach the 
formal predefined statistical significance. This could be due 
to the statistical power of the trials. Furthermore, dabigatran 
150 mg twice daily demonstrated a statistically significant 
reduction in ischemic stroke (the predominant type of stroke 
associated with atrial fibrillation) compared with warfarin, 
but the reduction in ischemic stroke did not reach statistical 
significance with apixaban versus warfarin. More studies are 
required to understand fully the relative merits of these new 
agents.
Safety profile of dabigatran
Hepatic safety has been carefully investigated in all clinical 
trials of dabigatran because of the reported experience with 
ximelagatran, an oral direct thrombin inhibitor associated 
with idiosyncratic hepatotoxicity.91–94
In the RE-MODEL, RE-NOVATE I and II, and 
RE-MOBILIZE trials, the incidence of liver enzyme 
elevations in patients treated with dabigatran was the same 
as or lower than that in patients treated with enoxaparin, 
which is not associated with hepatotoxicity. Liver enzyme 
elevations were infrequent and returned to baseline values 
in all patients.43,44,46,47 In the longer term, liver function 
tests from the RE-LY trial demonstrated that elevation 
of levels of serum aspartate aminotransferase or alanine 
aminotransferase to more than three times the upper limit of 
the normal range did not occur more frequently with either 
dose of dabigatran (2.1% and 1.9%) than with dose-adjusted 
warfarin (2.2%).81 Similarly, results from the RE-COVER 
trial showed no evidence of hepatotoxicity associated with 
dabigatran treatment.73 These findings from different patient 
populations treated with dabigatran for a variety of indications 
and treatment durations suggest that hepatotoxicity is not a 
class effect with oral direct thrombin inhibitors.
Concern regarding rebound coagulation effects following 
the cessation of thromboprophylactic agents requires careful 
investigation in clinical trials. In a pooled analysis of three 
  trials, one adjudicated acute coronary event was reported 
during 3 months of follow-up after use of dabigatran 220 mg 
once daily, two events after dabigatran 150 mg once daily, 
and 7 events after enoxaparin in orthopedic surgery, 
  suggesting no rebound coagulation effect once treatment with 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
53
Dabigatran in venous and arterial thromboembolismVascular Health and Risk Management 2012:8
dabigatran ends.48 Acute coronary syndrome rates were also 
similar between treatments in the RE-COVER trial.73
During the RE-LY trial, there was no statistically sig-
nificant difference in myocardial infarction rates between the 
dabigatran doses and warfarin, although the rates of myocar-
dial infarction were numerically higher with   dabigatran. The 
  overall rates were low (0.82, 0.81, and 0.64% per year with 
dabigatran 110 mg twice daily, dabigatran 150 mg twice daily, 
and warfarin, respectively).82 The incidence observed with 
warfarin was similar to that reported in the warfarin arms 
of previous clinical trials (eg, SPORTIF III and V , ACTIVE-
W).95–97 Similarly, the rates of myocardial infarction reported 
with ximelagatran and aspirin plus clopidogrel in the same 
studies were comparable with those seen for dabigatran in 
RE-LY.95–97 The rates with dabigatran were lower than reported 
for placebo.98
Conclusion
The Phase III trials of dabigatran have generated approxi-
mately 25,124 patient-years of experience to demonstrate the 
efficacy and safety profile of dabigatran for the prevention of 
venous and arterial thromboembolic disorders across multiple 
indications. Results from trials in orthopedic surgery show 
comparable efficacy and similar bleeding rates to enoxaparin, 
and dabigatran has been used in clinical practice in this indi-
cation since April 2008.
Results from the RE-COVER trial show that dabigatran has 
similar efficacy and significantly lower rates of major or clini-
cally relevant bleeding compared with warfarin in prevention 
of recurrent events after acute venous thromboembolism. In 
addition, results from the RE-LY trial demonstrate that dab-
igatran 150 mg twice daily has superior efficacy, similar rates 
of major bleeding, and a reduction in intracranial hemorrhage 
compared with warfarin for the long-term prevention of stroke 
in patients with atrial fibrillation. In contrast with the currently 
recommended and widely used oral anticoagulant agent war-
farin, dabigatran provides many advantages in this indication, 
including predictable anticoagulant effects, no food interactions, 
few drug interactions, and convenient long-term administration 
without the need for regular anticoagulation monitoring. In con-
clusion, dabigatran has the potential to improve the prevention 
and treatment of venous thromboembolism and the management 
of stroke prevention in patients with atrial fibrillation.
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